Auven Therapeutics operates as a private equity firm with a unique focus on life sciences, integrating an internal drug development company to enhance the management of its therapeutic assets. The firm addresses critical gaps in the biotechnology sector by providing funding and development expertise to small biotech companies while simultaneously working to fill the pipeline of late-stage clinical products for larger pharmaceutical companies. Auven's portfolio includes a diverse range of biologic and small molecule therapeutic candidates aimed at treating various conditions, including cancers, eye diseases, and orphan diseases. Notable products in their pipeline include Kiacta™, an investigational treatment for sarcoidosis, and Seciera™, a patented nanomicellar cyclosporine solution currently in Phase III clinical development for dry eye syndrome.

A significant aspect of Auven's strategy involves its investment in ADC Therapeutics, a company specializing in the development of proprietary Antibody Drug Conjugates (ADCs) for oncology. These ADCs utilize monoclonal antibodies that target specific tumor antigens, combined with potent pyrrolobenzodiazepine (PBD)-based warheads, allowing for highly selective cancer therapies with potentially fewer side effects. Auven's collaboration with ADC Therapeutics has led to multiple clinical trials, with several ADCs in various stages of development, including pivotal trials. Additionally, Auven has invested in Sprout Pharmaceuticals, which focuses on treatments for female sexual dysfunction, further diversifying its therapeutic offerings and investment strategy.

Virgin Islands, U.S.

Auven Therapeutics is a private equity firm pursuing an innovative life science investment strategy. Although it utilizes a fund structure, it also has an internal drug development company that allows it to more effectively manage drug development and grow the value of its therapeutic assets.

Auven Therapeutics

Company Details